- Stocks
- Pharma & Healthcare
- Lincoln Pharmaceuticals
Lincoln Pharmaceuticals share price
NSE: LINCOLNPharma & HealthcareDrug Manufacturers - Specialty & Generic
Lincoln Pharmaceuticals at a glance
Lincoln Pharmaceuticals (NSE: LINCOLN) closed at ₹533.40 on 19 Oct 2026, down 2.58% on the day. With a market capitalisation of ₹1,068 Cr, it ranks 1435th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.
At its last close the stock traded at 12.2× trailing earnings, against a return on equity of 11.6% in FY26. Over the past year the share price has risen 0.9%. Its 52-week range is ₹440.00 (28 Jan 2026) to ₹770.00 (27 May 2026); the last close is 30.7% below the high. Promoters held 49.78% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹1,068 CrRank 1435 on NSE
- P/E (trailing)
- 12.2×
- Price to book
- 1.49×FY26
- ROE
- 11.6%FY26
- ROCE
- 15.0%FY26
- Debt to equity
- 0.01FY26
- Net profit margin
- 13.1%FY26
- Book value / share
- ₹378.25FY26
- 52-week high
- ₹770.0027 May 2026
- 52-week low
- ₹440.0028 Jan 2026
- 1-year return
- +0.9%
- RSI (14-day)
- 32.7
Returns to 19 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | −2.58% | −2.6% | −10.9% | −10.2% | +0.9% |
Lincoln Pharmaceuticals financials
| Item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Revenue | ₹424 Cr | ₹472 Cr | ₹510 Cr | ₹581 Cr | ₹623 Cr | — |
| Operating profit | ₹84 Cr | ₹96 Cr | ₹100 Cr | ₹122 Cr | ₹109 Cr | — |
| Net profit | ₹62 Cr | ₹69 Cr | ₹73 Cr | ₹93 Cr | ₹82 Cr | — |
| EPS (₹) | ₹31.00 | ₹35.00 | ₹36.00 | ₹47.00 | ₹41.00 | — |
| Cash from operations | ₹69 Cr | ₹76 Cr | ₹39 Cr | ₹63 Cr | ₹93 Cr | — |
| Total debt | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Shareholders' equity | ₹375 Cr | ₹433 Cr | ₹502 Cr | ₹593 Cr | ₹672 Cr | ₹758 Cr |
Lincoln Pharmaceuticals shareholding pattern
| Holder | 31 Mar 2025 | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 49.78% | 49.78% | 49.78% | 49.78% | 49.78% | 49.78% |
| Foreign institutions | 5.00% | 5.14% | 4.72% | 4.70% | 5.19% | 4.60% |
| Domestic institutions | 0.01% | 0.01% | 0.01% | 0.01% | 1.09% | 0.27% |
| Non-institutions | 45.22% | 45.07% | 45.49% | 45.52% | 43.94% | 45.36% |
Lincoln Pharmaceuticals vs peers
The listed Pharma & Healthcare companies nearest to Lincoln Pharmaceuticals by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| GPTHEALTHGPT Healthcare | ₹139.50 | −0.36% | −6.4% | ₹1,145 Cr | 27.1 | — |
| BAJAJHCAREBajaj Healthcare | ₹339.90 | −2.05% | −27.4% | ₹1,144 Cr | 50.4 | — |
| BAFNAPHBafna Pharmaceuticals | ₹470.55 | +1.99% | +195.5% | ₹1,113 Cr | 100.3 | — |
| LINCOLNLincoln Pharmaceuticals | ₹533.40 | −2.58% | +0.9% | ₹1,068 Cr | 12.2 | — |
| SIGACHISigachi Industries | ₹26.70 | −4.13% | −32.9% | ₹1,020 Cr | — | — |
| LAXMIDENTLLaxmi Dental | ₹182.10 | −1.57% | −42.7% | ₹1,001 Cr | 34.6 | — |
| THEMISMEDThemis Medicare | ₹100.30 | −5.47% | −23.6% | ₹924 Cr | — | — |
Ask anything about Lincoln Pharmaceuticals
Pivot answers on the live chart with evidence you can check, and tests strategies against LINCOLN's own history. Try: “Why has LINCOLN moved over the last three months?” · “Backtest a 50-day moving-average crossover on LINCOLN over five years” · “Compare LINCOLN with GPTHEALTH on margins and valuation”
Frequently asked questions about Lincoln Pharmaceuticals
What is the share price of Lincoln Pharmaceuticals today?
Lincoln Pharmaceuticals (NSE: LINCOLN) last closed at ₹533.40 on 19 Oct 2026. Its 52-week high is ₹770.00 and its 52-week low is ₹440.00.
What is the market cap of Lincoln Pharmaceuticals?
Lincoln Pharmaceuticals' market capitalisation is ₹1,068 Cr (₹1,068 Cr) at the 19 Oct 2026 close, ranking 1435th among the NSE companies Pivot tracks.
What is the P/E ratio of Lincoln Pharmaceuticals?
Lincoln Pharmaceuticals trades at a trailing P/E of 12.2. The median P/E of the 4 closest Pharma & Healthcare peers by market cap is 50.4.
What is the ROE and ROCE of Lincoln Pharmaceuticals?
Return on equity was 11.6% in FY26 and return on capital employed was 15.0% in FY26 (consolidated figures).
Is Lincoln Pharmaceuticals a debt-free company?
Lincoln Pharmaceuticals is close to debt-free: its debt-to-equity ratio was 0.01 in FY26.
How has Lincoln Pharmaceuticals stock performed over the last year?
Lincoln Pharmaceuticals' share price has risen 0.9% over the past year, −10.2% over three months and −10.9% over one month, to the 19 Oct 2026 close.
What is the shareholding pattern of Lincoln Pharmaceuticals?
As of 30 Jun 2026: promoters 49.78%, foreign institutions 4.60%, domestic institutions 0.27%, non-institutions 45.36%.
Who are Lincoln Pharmaceuticals' competitors?
The listed Pharma & Healthcare companies closest to Lincoln Pharmaceuticals by market cap are GPT Healthcare, Bajaj Healthcare, Bafna Pharmaceuticals, Sigachi Industries, Laxmi Dental and Themis Medicare.
Is Lincoln Pharmaceuticals a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Lincoln Pharmaceuticals' price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on LINCOLN against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 19 Oct 2026 (returns and ratios at the 19 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with L · all NSE stocks · this page as text